Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [DEA # 207P]
 AGENCY: Drug Enforcement Administration (DEA), Justice.
 ACTION: Notice of proposed year 2001 aggregate production quotas.
 SUMMARY: This notice proposes initial year 2001 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).
 DATES: Comments or objections must be received on or before November 3, 2000.
 ADDRESSES: Send comments or objections to the Deputy Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn.: DEA Federal Register Representative (CCR).
 FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.


SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotes for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations. The proposed year 2001 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2001 to provide adequate supplies of each substance for: The estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes. In determining the proposed year 2001 aggregate production quotas, the Deputy Administrator considered the following factors: total actual 1999 and estimated 2000 and 2001 net disposals of each substance by all manufacturers; estimates of 2000 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; product development requirements of both bulk and finished dosage form manufacturers; projected demand as indicated by procurement quota applications filed pursuant to Section 1303.12 of Title 21 of the code of Federal Regulations; and other pertinent information. Pursuant to Section 1303 of Title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 2001, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 2000 year-end inventory and actual 2000 disposition data supplied by quota recipients for each basic class of Schedules I or II controlled substance. Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, and the Deputy Administrator hereby proposes that the year 2001 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows: Basic class
Proposed year 2001 quotasSchedule I:2,5-Dimethoxyamphetamine
15,501,0002,5-Dimethoxy-4-ethylamphetamine (DOET)
23-Methylfentanyl
143-Methylthiofentanyl
23,4-Methylenedioxyamphetamine (MDA)
253,4-Methylenedioxy-N-ethylamphetamine (MDEA)
303,4-Methylenedioxymethamphetamine (MDMA)
103,4,5-Trimethoxyamphetamine
24-Bromo-2,5-Dimethoxyamphetamine (DOB)
24-Bromo-2,5-Dimethoxyphenethylamine (2-CB)
24-Methoxyamphetamine
201,0004-Methylaminorex
24-Methyl-2,5-Dimethoxyamphetamine (DOM)
25-Methoxy-3,4-Methylenedioxyamphetamine
2Acetyl-alpha-methylfentanyl
2Acetyldihydrocodeine
2Acetylmethadol
2Allylprodine
2Alphacetylmethadol
7Alpha-ethyltryptamine
2Alphameprodine
2Alphamethadol
2Alpha-methylfentanyl
2Alpha-methylthiofentanyl
2Aminorex
7Benzylmorphine
2Betacetylmethadol
2Beta-hydroxy-3-methylfentanyl
2Beta-hydroxyfentanyl
2Betameprodine
2Betamethadol
2Betaprodine
2Bufotenine
2Cathinone
9Codeine-N-oxide
2Diethyltryptamine
2Difenoxin
9,000Dihydromorphine
634,000Dimethyltryptamine
2Gamma-hydroxybutyric acid
15,000,000Heroin
2Hydroxypethidine
2Lysergic acid diethylamide (LSD)
37Marihuana
350,000Mescaline
7Methaqualone
19Methcathinone
11Morphine-N-oxide
2N,N-Dimethylamphetamine
7N-Ethyl-l-Phenylcyclohexylamine (PCE)
5N-Ethylamphetamine
7N-Hydroxy-3,4-Methylenedioxyamphetamine
2Noracymethadol
2Norlevorphanol
2Normethadone
7Normorphine
7Para-fluorofentanyl
2Pholcodine
2Porpiram
415,000Psilocybin
2Psilocyn
2Tetrahydrocannabinols
131,000Thiofentanyl
2( print page 59215)Trimeperidine
2Schedule II:1-Phenylcyclohexylamine
121-Piperidinocyclohexanecarbonitrile (PCC)
10Alfentanil
3,000Alphaprodine
2Amobarbital
12Amphetamine
10,958,000Cocaine
251,000Codeine (for sale)
43,248,000Codeine (for conversion)
59,051,000Dextropropoxyphene
134,401,000Dihydrocodeine
272,000Diphenoxylate
401,000Ecgonine
51,000Ethylmorphine
12Fentanyl
440,000Glutethimide
2Hydrocodone (for sale)
21,417,000Hydrocodone (for conversion)
26,540,000Hydromorphone
1,409,000Isomethadone
12Levo-alphacetylmethadol (LAAM)
41,000Levomethorphan
2Levorphanol
15,000Meperidine
10,168,000Methadone (for sale)
8,347,000Methadone (for conversion)
60,000Methadone Intermediate
9,503,000Methamphetamine
2,226,000850,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,325,000 grams for methamphetamine for conversion to a Schedule III product; and 51,000 grams for methamphetamine (for sale)Methylphenidate
14,957,000Morphine (for sale)
14,706,000Morphine (for conversion)
117,675,000Nabilone
2Noroxymorphone (for sale)
25,000Noroxymorphone (for conversion)
3,180,000Opium
570,000Oxycodone (for sale)
46,680,000Oxycodone (for conversion)
449,000Oxymorphone
264,000Pentobarbital
22,037,000Phencyclidine
40Phenmetrazine
2Phenylacetone
10Secobarbital
12Sufentanil
1,000Thebaine
65,596,000
 The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations be established at zero. All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more or these issues warrant a hearing, the individual should so state and summarize the reasons for this belief. In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the 
                    **Federal Register,**
                     summarizing the issues to be heard and setting the time for the hearing. The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 13132, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 
                    *et seq.*
                     The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Dated: September 27, 2000. Julio F. Mercado, Deputy Administrator.


[FR Doc. 00-25421  Filed 10-3-00; 8:45 am] BILLING CODE 4410-09-M